Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Xavier C. Badoux(St George Hospital), Alessandra Ferrajoli(The University of Texas MD Anderson Cancer Center), Sijin Wen(The University of Texas MD Anderson Cancer Center), Stefan Faderl(Jazz Pharmaceuticals (United States)), Rachel L. Sargent(The University of Texas MD Anderson Cancer Center), Jan A. Burger(The University of Texas MD Anderson Cancer Center), Susan O’Brien(University of California, Irvine), William G. Wierda(The University of Texas MD Anderson Cancer Center), Michael J. Keating(The University of Texas MD Anderson Cancer Center)
Journal of Clinical Oncology
December 26, 2012
10.1200/jco.2012.42.8623
Cited by 153

Related Papers

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
|Blood|2008|3.2k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k